TDAP vaccine study for adults with burns
Part of Infections, Injuries & trauma, Lungs & breathing clinical trials.
This trial tests whether the TDAP vaccine (tetanus, diphtheria, and pertussis) helps adults with serious burns. It aims to see if the vaccine can improve recovery or prevent infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have a burn covering more than 10% of your body
- You are being treated at a participating hospital (Emory/Grady, USF, or USAISR)
- You or a legal representative can understand the study and agree to join
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects tissue and data from burn patients to build a better tool for predicting sepsis, a serious infection. If you qualify, your participation could help improve care for future burn patients.
This trial tests a special camera imaging system to assess burns on the head, hands, or feet. It may help determine if these burns can be imaged accurately to guide treatment decisions.
This trial tests an experimental medicine for people with small burns (10% or less of body surface). It aims to see if the treatment is safe and helps healing. The study has two phases: one for people getting skin grafts, and another for recent dermal burns.
This trial tests a new combination vaccine that protects against whooping cough, diphtheria, and tetanus for people aged 10 and older. It aims to see if the vaccine is safe and helps the body build immunity.
This trial tests a new drug called cP12 given through a vein to see if it is safe and how the body handles it. It is for adults who have a thermal burn covering 10% or less of their body within the first 2 to 24 hours after the burn happened.
This trial tests a new vaccine that protects against diphtheria, tetanus, and pertussis (whooping cough). It is for healthy infants who are about 2 months old and live permanently in the area. The goal is to see if the vaccine is safe and works well.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.